C-IJKGDeciduous Therapeutics
senescent cell clearance, immune surveillance activation
clearingimmunotherapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IJKG
C-IJKGC-IJKGsenescent cell clearance, immune surveillance activation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
In this episode of the BCI Podcast, we are joined by Robin Mansukhani, CEO of Deciduous Therapeutics, a biotech company pioneering new approaches in longevity and age-related disease treatments. Robin shares his journey into biotech, the groundbreaking work at Deciduous Therapeutics, and his vision for the future of healthcare. Topics Discussed: ✔️ Robin’s journey into biotech and entrepreneurship ✔️ How Deciduous Therapeutics is tackling age-related diseases ✔️ The role of senescent cell-targeting therapies in longevity ✔️ Challenges and opportunities in biotech innovation ✔️ Advice for aspiring biotech entrepreneurs Don’t miss this insightful conversation on the future of biotech and longevity! 🔔 Subscribe for more episodes featuring industry leaders in biotech, life sciences, and innovation. 👍 Like, Comment & Share if you enjoyed this episode! 📢 Follow us on: 🔹 LinkedIn: https://www.linkedin.com/company/bcipodcast 🔹 Website: www.bcipodcast.eu #BCIPodcast, #RobinMansukhani,
A while back, I had an amazing chat with Robin Mansukhani, CEO of Deciduous Therapeutics. He shared incredible insights into launching his biotech startup, but one story stood out: how he landed his first VC job right out of college! It’s a great reminder that bold moves can shape your entire career. Check out this clip where Robin shares his journey—perfect for anyone looking to break into venture capital or entrepreneurship. #StartupJourney #CareerTips #Biotech #Entrepreneurship
Robin Mansukhani, Deciduous Therapeutics, USA, presents at the 11th Aging Research and Drug Discovery meeting: Restoring Immune Function to Ablate Senescent Cells and Treat Diseases of Aging
Deciduous CEO Robin Mansukhani discusses how their company is working on harnessing the immune system to treat diseases of aging. Robin explains the concept of senescent cells and how their accumulation can lead to various age-related diseases such as pulmonary fibrosis, type 2 diabetes, and even dementias. He also shares insights on the potential of longevity therapeutics to revolutionize medicine by targeting multiple indications simultaneously.
Panel - "Longevity Startups - Conventional to Longevity Biotech," at the Longevity+DeSci Summit NYC (EARD 2023) hosted by Lifespan.io. Speakers: Matthew O'Connor -Co-CEO at Cyclarity Therapeutics J. Scotch Mcclure -Founder, CEO, and Chairman at Maxwell Biosciences Robin Mansukhani -Managing Partner at Deciduous Therapeutics FOLLOW US ▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀ https://www.lifespan.io https://twitter.com/lifespanio https://www.facebook.com/lifespanio https://www.instagram.com/lifespan.io HOW CAN YOU SUPPORT US? ▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀ Lifespan.io, a 501(c)(3) nonprofit organization. ► Support us with monthly donations by becoming a Lifespan Hero: https://www.lifespan.io/support ► Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1 ► Learn more, and help us: https://www.lifespan.io #longevity #EARD2023 #desci #decentralized #biotechnology #biology #healthscience #livelonger #agingbackwards #lifespan #healthspan #biotech #biotechnology #longevity #longev
Discover what I learned from senescence research that changed everything about aging, longevity, and the immune system. Explore the impact of natural killer T cells and senescent cells on healthspan in this biotechnology video. 9. 7. summary In this episode of Radh Diaries, host Kaushik Trivedi engages with Robin Mansukhani, CEO of Deciduous Therapeutics, to explore the intersection of aging, cellular senescence, and innovative therapeutic approaches. The conversation begins with a mythological tale of Tithonus, reflecting on the implications of aging and the quest for longevity. Robin shares his journey from venture capital to biotech, emphasizing the importance of immune activation in combating aging. The discussion delves into the role of natural killer T cells, therapeutic strategies, and the potential of natural remedies like intermittent fasting. Challenges in the biotech field and future opportunities in longevity research are also examined, alongside insights into leadership a
Discover what I learned from senescence research that changed everything about aging, longevity, and the immune system. Explore the impact of natural killer T cells and senescent cells on healthspan in this biotechnology video. 9. 7. summary In this episode of Drug Diaries, host Kaushik Trivedi engages with Robin Mansukhani, CEO of Deciduous Therapeutics, to explore the intersection of aging, cellular senescence, and innovative therapeutic approaches. The conversation begins with a mythological tale of Tithonus, reflecting on the implications of aging and the quest for longevity. Robin shares his journey from venture capital to biotech, emphasizing the importance of immune activation in combating aging. The discussion delves into the role of natural killer T cells, therapeutic strategies, and the potential of natural remedies like intermittent fasting. Challenges in the biotech field and future opportunities in longevity research are also examined, alongside insights into leadership a
Discover what I learned from senescence research that changed everything about aging, longevity, and the immune system. Explore the impact of natural killer T cells and senescent cells on healthspan in this biotechnology video. 9. 7. summary In this episode of Drug Diaries, host Kaushik Trivedi engages with Robin Mansukhani, CEO of Deciduous Therapeutics, to explore the intersection of aging, cellular senescence, and innovative therapeutic approaches. The conversation begins with a mythological tale of Tithonus, reflecting on the implications of aging and the quest for longevity. Robin shares his journey from venture capital to biotech, emphasizing the importance of immune activation in combating aging. The discussion delves into the role of natural killer T cells, therapeutic strategies, and the potential of natural remedies like intermittent fasting. Challenges in the biotech field and future opportunities in longevity research are also examined, alongside insights into leadership a
Discover what I learned from senescence research that changed everything about aging, longevity, and the immune system. Explore the impact of natural killer T cells and senescent cells on healthspan in this biotechnology video. 9. 7. summary In this episode of Drug Diaries, host Kaushik Trivedi engages with Robin Mansukhani, CEO of Deciduous Therapeutics, to explore the intersection of aging, cellular senescence, and innovative therapeutic approaches. The conversation begins with a mythological tale of Tithonus, reflecting on the implications of aging and the quest for longevity. Robin shares his journey from venture capital to biotech, emphasizing the importance of immune activation in combating aging. The discussion delves into the role of natural killer T cells, therapeutic strategies, and the potential of natural remedies like intermittent fasting. Challenges in the biotech field and future opportunities in longevity research are also examined, alongside insights into leadership a
Discover what I learned from senescence research that changed everything about aging, longevity, and the immune system. Explore the impact of natural killer T cells and senescent cells on healthspan in this biotechnology video. 9. 7. summary In this episode of Drug Diaries, host Kaushik Trivedi engages with Robin Mansukhani, CEO of Deciduous Therapeutics, to explore the intersection of aging, cellular senescence, and innovative therapeutic approaches. The conversation begins with a mythological tale of Tithonus, reflecting on the implications of aging and the quest for longevity. Robin shares his journey from venture capital to biotech, emphasizing the importance of immune activation in combating aging. The discussion delves into the role of natural killer T cells, therapeutic strategies, and the potential of natural remedies like intermittent fasting. Challenges in the biotech field and future opportunities in longevity research are also examined, alongside insights into leadership a
Discover what I learned from senescence research that changed everything about aging, longevity, and the immune system. Explore the impact of natural killer T cells and senescent cells on healthspan in this biotechnology video. 9. 7. summary In this episode of Drug Diaries, host Kaushik Trivedi engages with Robin Mansukhani, CEO of Deciduous Therapeutics, to explore the intersection of aging, cellular senescence, and innovative therapeutic approaches. The conversation begins with a mythological tale of Tithonus, reflecting on the implications of aging and the quest for longevity. Robin shares his journey from venture capital to biotech, emphasizing the importance of immune activation in combating aging. The discussion delves into the role of natural killer T cells, therapeutic strategies, and the potential of natural remedies like intermittent fasting. Challenges in the biotech field and future opportunities in longevity research are also examined, alongside insights into leadership a
Discover what I learned from senescence research that changed everything about aging, longevity, and the immune system. Explore the impact of natural killer T cells and senescent cells on healthspan in this biotechnology video. 9. 7. summary In this episode of Drug Diaries, host Kaushik Trivedi engages with Robin Mansukhani, CEO of Deciduous Therapeutics, to explore the intersection of aging, cellular senescence, and innovative therapeutic approaches. The conversation begins with a mythological tale of Tithonus, reflecting on the implications of aging and the quest for longevity. Robin shares his journey from venture capital to biotech, emphasizing the importance of immune activation in combating aging. The discussion delves into the role of natural killer T cells, therapeutic strategies, and the potential of natural remedies like intermittent fasting. Challenges in the biotech field and future opportunities in longevity research are also examined, alongside insights into leadership a
Discover what I learned from senescence research that changed everything about aging, longevity, and the immune system. Explore the impact of natural killer T cells and senescent cells on healthspan in this biotechnology video. 9. 7. summary In this episode of Drug Diaries, host Kaushik Trivedi engages with Robin Mansukhani, CEO of Deciduous Therapeutics, to explore the intersection of aging, cellular senescence, and innovative therapeutic approaches. The conversation begins with a mythological tale of Tithonus, reflecting on the implications of aging and the quest for longevity. Robin shares his journey from venture capital to biotech, emphasizing the importance of immune activation in combating aging. The discussion delves into the role of natural killer T cells, therapeutic strategies, and the potential of natural remedies like intermittent fasting. Challenges in the biotech field and future opportunities in longevity research are also examined, alongside insights into leadership a
Discover what I learned from senescence research that changed everything about aging, longevity, and the immune system. Explore the impact of natural killer T cells and senescent cells on healthspan in this biotechnology video. 9. 7. summary In this episode of Drug Diaries, host Kaushik Trivedi engages with Robin Mansukhani, CEO of Deciduous Therapeutics, to explore the intersection of aging, cellular senescence, and innovative therapeutic approaches. The conversation begins with a mythological tale of Tithonus, reflecting on the implications of aging and the quest for longevity. Robin shares his journey from venture capital to biotech, emphasizing the importance of immune activation in combating aging. The discussion delves into the role of natural killer T cells, therapeutic strategies, and the potential of natural remedies like intermittent fasting. Challenges in the biotech field and future opportunities in longevity research are also examined, alongside insights into leadership a
Robin Mansukhani is the co-founder and CEO of Deciduous Therapeutics, a quadraScope portfolio company that harnesses the immune system to eliminate senescent cells. This innovation holds the potential to extend healthspan and treat metabolic and fibrotic diseases. Deciduous' website: https://www.deciduoustx.com quadraScope's website: https://quadrascope.com/ Robin’s LinkedIn profile: https://www.linkedin.com/in/robin-mansukhani-8633653/ José’s LinkedIn profile: https://www.linkedin.com/in/jose-navarro-betancourt/ #investing #longevity #biotechnology #senescence
Robin Mansukhani, CEO of Deciduous Therapeutics, presents at the Rejuvenation Startup Summit 2024 Connect to Forever Healthy: * Videos: https://forever-healthy.org/videos/ * News: https://forever-healthy.org/news/ * LinkedIn: https://www.linkedin.com/company/forever-healthy-foundation/
Dive into the research that Robin and his team have done in-house and their secret sauce, as well as exploring the current state of research on senescent cell elimination and its potential impact on healthspan and lifespan. Robin will also share his thoughts on the development pipeline for Deciduous Therapeutics' immune mediated senolysis drugs, and how they differ from other companies in the field of immune mediated senolysis. Robin Mansukhani links https://www.linkedin.com/in/robin-mansukhani-8633653/ https://www.deciduoustx.com/ PODCAST INFO: The Learning With Lowell show is a series for the everyday mammal. In this show we’ll learn about leadership, science, and people building their change into the world. The goal is to dig deeply into people who most of us wouldn’t normally ever get to hear. The Host of the show – Lowell Thompson- is a lifelong autodidact, serial problem solver, and founder of startups. LINKS Youtube: https://www.youtube.com/channel/UCzri06unR-lMXbl6sqWP_-Q You
This week on the Life Science Success Podcast my guest is Robin Mansukhani. Robin is the CEO of Deciduous Therapeutics, a venture backed startup developing novel immunotherapies to treat age related diseases. Additionally, he co-founded BlueStamp Engineering, an intensive, project based engineering program for high school students in NYC, San Francisco, and Palo Alto.
Emerging Company Showcase Targeting Metabesity October 13, 2022
Robin Mansukhani, CEO of Deciduous Therapeutics at Rejuvenation Startup Summit 2022 Connect to Forever Healthy: * Videos: https://forever-healthy.org/videos/ * News: https://forever-healthy.org/news/ * LinkedIn: https://www.linkedin.com/company/forever-healthy-foundation/
Today I am joined by Robin Mansukhani, CEO and Dr. Anil Bhushan, Chief Scientist of Deciduous Therapeutics, a venture-backed start-up developing novel immunotherapies to treat age related diseases. Robin has also been an advisor to several early stage biotech companies in the Aging and CNS space including Therini Bio and Reservoir Neurosciences. Previously, Robin co-founded and served as President and CEO of Alzeca Biosciences, a diagnostic imaging company for CNS disorders, which is supported by venture investors, the Alzheimer's Drug Discovery Foundation, and an NIH Direct to Phase 2 Grant. Robin has been an invited keynote speaker both domestically and abroad, including TEDx. Previously, Mr. Mansukhani worked in early stage venture capital at The Maple Fund and investment banking at Axiom Capital. Mr. Mansukhani holds a B.S. in Biochemistry from Case Western Reserve University. Dr. Bhushan is the scientific founder of Deciduous where his lab was one of the first to show the role
Are longevity therapeutics a pipe dream reserved for the super-rich, or will they have a tangible impact on population life expectancy? This session is co-hosted by an expert in the field (Trend Host) and an actuary (Impact Host) and is designed as a conversation between intelligent people which draws out both what is new, and how it will affect longevity in the real world. • Trend Host: Robin Mansukhani, CEO, Deciduous Therapeutics • Impact Host: Peter Joshi, Actuary and Genomicist The #Longevity Leaders channel features sessions from the Longevity Leaders Congress, where our mission is to advance innovations that will extend human #healthspan and enable financial, physical and mental #wellness in later life. Sessions feature influential leaders from the worlds of ageing science, consumer products, finance, technology and investment. The events sit at the centre of a global ecosystem, connecting people, knowledge and investment to address the impact of how we age and how we cate
Y Series Film Production Present New Upcoming Garhwali Video Song Doob Dubyaa Wegi Pipal Daalee (डुब डुब्या ह्वेगी पिपल्द डाली) || Singer Lyrics & Music - Dr. Shashi Bhushan Maithani Ji!! Music Aarranger - Rajkumar Bharati Ji!! Producer - Vipin Maithani Ji!! Director - Vipin Maithani & Sohan Chauhan Ji!! Cinematographer & Editor - Govind Negi!! Drone - Yuvi Negi (Yuddhveer)!! Recorded By - Pulse Studio!! Recordist - Rajkumar Bharat Ji!! Mixing - Ranjeet singh!! Artist - Rhythm & Gaurav Maithani!! Guitar - Vipin Maithani!! Sitar - Agni Varma!! Flute - Mahesh!! Voilin - Shobhit Bharati Ji!! Flute - Mahesh!! Chorus - Anju Bisht & Renu Bala ji!! People Daily Pippa Dale Pippa Deeley\Know More - !! Welcome to Pipal Tree Hotel-About Pipal Tree !Pipal India: Buy Pipal Products Online at Best Prices | Snapdealपीपल - आध्यात्मिक जगतpipal - Meaning in Punjabi - pipal in Punjabi - Shabdkosh पीपल (अंग्रेज़ी: सैकरेड फिग, संस्कृत:अश्वत्थ) भारत, नेपाल, श्री लंका
LifeSpan Vision Ventures Invests in Deciduous Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country LifeSpan Vision Ventures Invests in Deciduous Therapeutics October 3, 2023 | 1 min read Twitter LinkedIn Facebook Email Print LifeSpan Vision Ventures announced an investment in Deciduous Therapeutics, a pioneering longevity biotechnology company dedicated to enhancing human healthspan by developing innova … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Deciduous Therapeutics Announces Appointments to the Board, SAB, and Advisor Roles - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Deciduous Therapeutics Announces Appointments to the Board, SAB, and Advisor Roles October 27, 2021 | 3 min read Twitter LinkedIn Facebook Email Print Deciduous Therapeutics announced today the appointment of an independent board member, additional Scientific Advisory Board members, and compa … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
#018: Anil Bhushan (Deciduous Therapeutics) - July 1st, 2021 | The Longevity Biotech Show Cancel Home Subscribe Profile The Longevity Biotech Show https://feed.podbean.com/longevitybiotechshow/feed.xml 10.4K Downloads 14 Episodes Share RSS A weekly live audience show featuring the people building and funding companies that are extending healthy human lifespan. Join us Thursdays on Clubhouse and check the show schedule on longevitybiotechshow.com Hosted by Nathan Cheng (founder @ Longevity Marketcap // Longevity List) and Robert Ziman (Cohen Lab). A weekly live audience show featuring the peopl
#018: Anil Bhushan (Deciduous Therapeutics) - July 1st, 2021 - The Longevity Biotech Show | Podcast on Spotify
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
A Shared Passion for Healthy Longevity Inspired this Alumni Venture Fund Investment | Veale Institute for Entrepreneurship | Case Western Reserve University Skip to main content Go to case.edu Veale Institute for Entrepreneurship Resources For: Students Faculty Search Submit Search Education Undergraduate Entrepreneurship Programs Graduate Entrepreneurship Programs Fellowships Veale Snyder Fellowship Program Veale Faculty Fellowship Campus Fellowships Funding THINK, DO, THRIVE Grant Program Student Club Grants CWRU Alumni Venture Fund Sopko Travel Grant Startup Support LaunchNET The Veale Entr … orators News and Media CWRU Entrepreneurs Toggle navigation Navigation + Search Submit Search Education Undergraduate Entrepreneurship Programs Graduate Entrepreneurship Programs Fellowships Veale Snyder Fellowship Program Veale Faculty Fellowship Campus Fellowships Funding THINK, DO, THRIVE Grant Program Student Club Grants CWRU Alumni Venture Fund Sopko Travel Grant Startup Support LaunchNET The Veale Entrepreneurship Lab Expert in Residence Program Events and Workshops Ent … trepreneurs A Shared Passion for Healthy Longevity Inspired this Alumni Venture Fund Investment About Our Mission Our Team Our Collaborators News and Media CWRU Entrepreneurs A Shared Passion for Healthy Longevity Inspired this Alumni Venture Fund Investment Article Date April 03, 2023 L to R: Robin Mansukhani (CWR ’05) and Ammar Kazi (CWR ‘22) In 2020, Robin Mansukhani (CWR ’05), CEO of Deciduous Therapeutics , was surprised when he received a cold call from Michael Goldberg … Reserve University. Mansukhani was just buttoning up a time-intensive Series A fund raising round for his early-stage startup. “Michael explained that the Veale Institute had a new funding mechanism for startups, the CWRU Alumni Venture Fund. My first inclination was to pass; our fundraising round was well-baked. As we talked, I became open to the idea of having CWRU on our cap table.” Mansukhani’s relationship with CWRU goes back 20 years when he was still a high school stu … it was just a start. And he agreed to participate in the CWRU’s Alumni Venture Fund. Goldberg wasn’t the only one pleased that Deciduous Therapeutics would be considered for funding. Ammar Kazi (CWR ‘22), a student fellow with the Alumni Venture Fund, was excited about playing a leading role in the due diligence process. Throughout high school,
Robin Mansukhani, CEO of Deciduous Therapeutics, is keynote speaker to the 2060 Longevity Forum, happening in beautiful Aix-en-Provence, South of France, on the 30th and 31st of August, 2025. The… | Gabriel Cian LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any
Interview with Robin Mansukhani, CEO and Anil Bhushan, Chief Scientist of Deciduous Therapeutics – Scott Amyx Skip to content Scott Amyx About Scott Astor Perkins Speaking Innovation Forbes Books Newsroom Contact Scott Amyx About Books Climate Change Contact Events Forbes Home Innovation Newsroom Privacy Speaking Strive Stories Terms of Use Interview with Robin Mansukhani, CEO and Anil Bhushan, Chief Scientist of Deciduous Therapeutics By Scott Amyx / July 19, 2022 Today I am joined by Robin Mansukhani, CEO and Dr. Anil Bhushan, Chief Scientist of Deciduous Therapeutics, a venture-backed … , the Alzheimer’s Drug Discovery Foundation, and an NIH Direct to Phase 2 Grant. Robin has been an invited keynote speaker both domestically and abroad, including TEDx. Previously, Mr. Mansukhani worked in early stage venture capital at The Maple Fund and investment banking at Axiom Capital. He has also co-founded BlueStamp Engineering, an intensive, project-based engineering program for high school students. Robin previously served a term in AmeriCorps where he led hea
Deciduous Therapeutics divulges new iNKT activators | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energi
--> Deciduous Therapeutics Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immortal An
Deciduous Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Deciduous Therapeutics, Inc. Startups | Holding Company | 2018 | California, United States | 10-50 | www.deciduoustx.com Startups | Holding Company | 2018 | California, United States | 10-50 | www.deciduoustx.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Respiratory Diseases Nervous System Diseases Small molecule drug Diseas … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Home - Deciduous Therapeutics Inc. Home About News Careers Contact Deciduous Therapeutics aims to positively impact human health span through the development of novel medicines that activate the endogenous immune mechanism responsible for the elimination of senescent cells. Our Science Senescent cells, which are characterized by irreversible damage and an inflammatory secretome, are considered a key driving force behind many age-related diseases. Due to a failure in immune surveillance, senescent cells accumulate and impact their local environment by inducing inflammation and promoting extrace
Deciduous Therapeutics — BOLD Capital Partners Menu Investors Navigation Home Team Companies News & Ideas Careers Investor Portal Address BOLD Capital Partners BOLD Longevity Growth 225 Santa Monica Blvd, Suite 900 Santa Monica, CA 90401 100 Cambridge Street Boston, MA 02114 Google Maps Contacts Email us Socials LinkedIn Twitter Recent Investments Hosta AI Centivax Near Space Labs ProRata.ai Aqtual Deciduous Therapeutics - Deciduous Therapeutics - Deciduous Therapeutics - Deciduous is developing novel immuno-therapies to ablate senescent cells and systemically
Robin Mansukhani, CEO of Deciduous Therapeutics | Partnology Skip to content Mission Team Join Us Offerings Executive Search Investment Insights Testimonials Case Studies Contact Mission Team Join Us Offerings Executive Search Investment Insights Testimonials Case Studies Contact All Insights Robin Mansukhani, CEO of Deciduous Therapeutics Welcome to Partnology’s Biotech Leader Spotlight Series, where we highlight the remarkable accomplishments and visionary leadership of biotech industry pioneers. This series is about showcasing the groundbreaking strides made by exceptional leaders who have … g TEDx. Previously Robin has worked in early stage venture capital at The Maple Fund and investment banking at Axiom Capital. In the community, he co-founded BlueStamp Engineering, an intensive, project based engineering program for high school students in NYC, San Francisco, and Palo Alto. He has also served a term in AmeriCorps. Mr. Mansukhani holds a B.S. in Biochemistry from Case Western Reserve University. He lives in San Francisco with his wife, three daughters, and dog … ty but soon realized I didn’t want a traditional bench role. When a new venture fund was forming in Cleveland, I joined—initially unpaid—because the prospect of creating and investing in seed-stage companies out of academia fascinated me. As the fund gained traction, I was eventually brought on formally, and the experience whetted my appetite to run companies rather than just back them. That led me to a boutique investment bank in New York that had a new interest in company f … I wouldn’t say you can take the exact skill set or approach from Company A and apply it directly to Company B. What’s most important is having a clear framework for identifying the key inflection points—and knowing how to get to them as quickly and efficiently as possible. In science, especially when you’re developing new molecules, targeting novel pathways, or aiming to demonstrate a new therapeutic effect, the number of ideas you can generate is virtually infinite. S … nsistent over the past nine months, remain an important option. Having a robust grant strategy—submitting multiple proposals—can be one of the most effective ways to offset the downturn in venture and pharma VC funding. In short, cutting unnecessary spend and aggressively exploring alternative funding sources are probably the best ways to navigat
#018: Anil Bhushan (Deciduous …–The Longevity Biotech Show – Apple Podcasts Search Home New Top Charts Search 1 July 2021 1hr 5min #018: Anil Bhushan (Deciduous Therapeutics) - July 1st, 2021 The Longevity Biotech Show Play Anil Bhushan is a professor at the University of California San Francisco and also a co-founder of Deciduous Therapeutics, a longevity biotech company developing an immunotherapy to remove senescent cells. Episode Webpage Information Show The Longevity Biotech Show Frequency Updated weekly Published 1 July 2021 at 23:13 UTC Length 1hr 5min Episode 18 Rating Clean Pola
News - Deciduous Therapeutics Inc. Home About News Careers Contact News Announcements May 2021 Announcement Invariant natural killer T cells coordinate removal of senescent cells Failure of endogenous immune surveillance mechanisms to remove senescent cells drives the progression of diseases. The identity of the endogenous immune surveillance that mediated senescent cell clearance in vivo is not clear. This paper describes how lipid antigen presentation to activate iNKT cells can constitute an endogenous surveillance system that can be manipulated to clear senescent cells in disease models. RE
Deciduous Therapeutics - The Immunology Podcast Skip to main content Hit enter to search or ESC to close Search Close Search search Menu Episodes Upcoming Guests About Our Story Hosts Resources Newsletter Contact Us Share Your Feedback Listen Now search Listen Now Episodes Upcoming Guests About Our Story Hosts Resources Newsletter Contact Us Share Your Feedback Tag Deciduous Therapeutics Ep. 15: “Tuning the Immune Response” Featuring Dr. Anil Bhushan Aging Immunology Immunotherapy Industry Senescence Ep. 15: “Tuning the Immune Response” Featuring Dr. Anil Bhushan Dr. An
About Us - Deciduous Therapeutics Inc. Home About News Careers Contact About Us Our team is composed of scientists, entrepreneurs, and drug hunters who share a collective vision and passion for profoundly impacting how we age. Team Robin Mansukhani | CEO and Co-Founder Robin Mansukhani is CEO and Co-Founder of Deciduous Therapeutics. Previously, he co-founded and served as President & CEO of Alzeca Biosciences, an Alzheimer’s/CNS diagnostic imaging company which was supported by venture investors and the NIH. He has been an invited speaker both domestically and abroad, including TEDx. Previous … g TEDx. Previously Robin has worked in early stage venture capital at The Maple Fund and investment banking at Axiom Capital. In the community, he co-founded BlueStamp Engineering, an intensive, project based engineering program for high school students in NYC, San Francisco, and Palo Alto. He has also served a term in AmeriCorps. Mr. Mansukhani holds a B.S. in Biochemistry from Case Western Reserve University. He lives in San Francisco with his wife, three daughters, and ind … logy at the University of California, San Francisco, followed by a postdoctoral fellowship at Lawrence Berkeley National Laboratory’s Molecular Foundry. She led chemistry development of DNA-encoded peptidomimetic libraries at Trilo Therapeutics. Her past research has focused on developing nanoparticle sensors for biological and deep-tissue imaging. LinkedIn Parvez Rashid | Associate Scientist Parvez Rashid is a Senior Research Associate with over 10 years of industry experien … her venture full time. Laura is currently a full-time partner at The Longevity Fund, an early stage venture capital fund backing companies which target the aging process to treat disease, with investments in gene editing, small molecule therapeutics, and novel methods to treat disease.’ Robert Forrester | Board Member Robert Forrester is the co-founder and CXO of EQRx. Robert has over 20 years of experience as the CEO, COO or CFO of both private and public life science compa … sts) from 2009 – 2015. Dr. Kronenberg was awarded the AAI Distinguished Service award in 2016 and was elected a Distinguished Fellow of AAI in 2019. Dr. Kronenberg is a leader in the field of iNKT cell biology and mucosal biology. His lab studies innate-like T lymphocytes, including natural killer T cells (NKT cells), mucosal-associated invariant